無料セミナー : 2020年3月4日『Future of Immuno-Oncology 免疫腫瘍学の未来』 DelveInsight Business Research共同開催

TEL: 044-952-0102

世界のRNA干渉 (RNAi) 市場: - 成長、動向、予測

RNA-interference (RNAi) Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 629144
出版日 ページ情報 英文 114 Pages
納期: 2-3営業日
本日の銀行送金レート: 1USD=110.80円で換算しております。
Back to Top
世界のRNA干渉 (RNAi) 市場: - 成長、動向、予測 RNA-interference (RNAi) Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年03月01日 ページ情報: 英文 114 Pages

当レポートでは、世界のRNA干渉 (RNAi) 市場について調査し、市場の概要と用途別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場概要

  • 現在の市場シナリオ
  • ポーターズファイブフォース分析

第6章 促進因子、阻害因子、機会、課題分析

  • 市場促進因子
  • 市場阻害因子
  • 機会
  • 主な課題

第7章 市場セグメンテーション

  • 用途別
    • 創薬・開発
    • 治療薬
      • 腫瘍
      • 眼内疾患
      • 呼吸器疾患
      • B型肝炎、C型肝炎
      • 自己免疫性肝炎
      • 神経疾患
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合環境

  • 合併・買収分析
  • 協定、連携、提携
  • 新製品上市

第9章 主要参入企業

  • Alnylam Pharmaceuticals
  • Quark Pharmaceuticals Inc.
  • Qiagen NV
  • Merck & Co. Inc. (Sigma Aldrich)
  • Thermo Fisher Scientific Inc.
  • Silence Therapeutics
  • Benitec Biopharma Ltd
  • Ionis Pharmaceuticals Inc.
  • Arcturus Therapeutics
  • Takara Bio Inc. (Clonetch)
  • Dharmacon (Horizon Discovery Group Company)

第10章 市場の将来

Product Code: 53709

Market Overview

The RNA-interference (RNAi) market is expected to witness a CAGR of 20.2% during the forecast period. Certain factors that are driving the market growth include the increasing number of applications in molecular diagnostics, particularly in cancer and improving synthetic delivery carriers and chemical modifications to RNA.

Cancer diagnosis and treatment is currently undergoing a shift with the incorporation of RNAi techniques in personalized medicine and molecular diagnostics. The availability of high throughput techniques for the identification of altered cellular molecules and metabolites allows the use of RNAi techniques in various cancer diagnosis and targeting approaches. For diagnostic purposes, small interfering RNAs (siRNA) or microRNAs (miRNA) can be utilized. The commercial availability of siRNAs to silence virtually any gene in the human genome is dramatically accelerating the pace of molecular diagnosis and biomedical research. Thus, increasing the application of RNAi in molecular diagnosis and its viability as a therapeutic technique is expected to drive the growth of the RNAi market during the forecast period.

However, in recent years, there has been a decline in FDA drug approval rates. Getting FDA approval for a new drug has become extremely challenging. It approved less than half the number of new drugs in 2016 (19 so far) when compared to 2015 (45 total) and 2014 (41 total). Hence, despite the large investments, there has been a decline in the number of innovative drugs manufactured. FDA explains manufacturing standards and other complying issues as the major reasons for this declining trend. This can impede the growth of the RNAi therapeutics, especially since the miRNAs and siRNAs fall into the relatively new field of genetic medicine, wherein they may require more intensified clinical trials. The highly extensive clinical trials effectively result in low approval rates of drugs. This would mean that the stringent guidelines will be a major restraint for the growth of the market.

Scope of the Report

RNA interference is a biological process in which the RNA molecules are observed to inhibit gene expression or translation, by neutralizing the targeted mRNA molecules. Earlier, RNAi was identified by other names, such as co-suppression, post-transcriptional gene silencing (PTGS), and quelling. The extensive study of each of these apparently different processes clarified that the identity of these phenomena were all in fact RNAi.

Key Market Trends

Oncology is Expected to Hold Significant Market Share in the Therapeutics Type

According to the World Health Organization, cancer is the second leading cause of death worldwide and was responsible for 8.8 million deaths in 2015. Globally, nearly one in six deaths can be attributed to cancer. Cancer is one of the leading causes of morbidity and mortality across the globe, with approximately 14 million new cases in 2012. The number of new cases is expected to rise by about 70% over the next two decades.

Recent advancements, such as the development of small interfering RNA (siRNA) tolerant to nucleases and the development of non-viral vectors, such as cationic liposomes and nanoparticles, can overcome this obstacle and facilitate the clinical use of RNAi-based therapeutics in the treatment of cancer. These developments are anticipated to help the growth of the global market in the large cancer therapy market.

North America Dominates the Market and Expected to do the Same in the Forecast Period

There are a large number of companies and research institutes in the country, increasingly investing in research on drug discovery using RNAi technology. The recent technological and medical advances are available in North America. Other factors, such as the growing population and high incidences of diseases, such as liver disorders and cancers, are fuelling the regional growth of this market.

Competitive Landscape

The RNA-interference (RNAi) market is highly competitive and consists of a few major players. Companies like Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Gradalis, miRagen Therapeutics, among others, hold the substantial market share in the RNA-interference (RNAi) market.

Various developments have recently been taking place in the market, such as in November 2017, Arcturus Therapeutics merged with Alcobra Ltd. In October 2017, Alnylam and Vir formed a strategic alliance to advance RNAi therapeutics for infectious diseases.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of Applications in Molecular Diagnostics, Particularly in Cancer
    • 4.2.2 Improving Synthetic Delivery Carriers and Chemical Modifications to RNA
  • 4.3 Market Restraints
    • 4.3.1 Stringent FDA Regulations and Changing Reimbursement Environment
    • 4.3.2 Unstable Potentially Immunogenic Nature of RNA
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 Application
    • 5.1.1 Drug Discovery and Development
    • 5.1.2 Therapeutics
      • Oncology
      • Ocular Disorders
      • Respiratory Disorders
      • Hepatitis B and C
      • Autoimmune Hepatitis
      • Neurological Disorders
      • Other Therapeutics
    • 5.1.3 Other Applications
  • 5.2 Geography
    • 5.2.1 North America
      • US
      • Canada
      • Mexico
    • 5.2.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.2.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.2.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Alnylam Pharmaceuticals
    • 6.1.2 Arcturus Therapeutics
    • 6.1.3 Arrowhead
    • 6.1.4 Dicerna Pharmaceuticals
    • 6.1.5 Quark Pharmaceuticals Inc.
    • 6.1.6 Ionis Pharmaceuticals Inc.
    • 6.1.7 Merck & Co. Inc. (Sigma Aldrich)
    • 6.1.8 Silence Therapeutics PLC
    • 6.1.9 Qiagen NV
    • 6.1.10 Phio Pharmaceuticals Corp.
    • 6.1.11 Thermo Fisher Scientific Inc.


Back to Top